REG - ReNeuron Group plc - Result of AGM <Origin Href="QuoteRef">RQE.L</Origin>

ReNeuronAnnouncement

24/09/2015 13:50

RNS Number : 1335A
ReNeuron Group plc
24 September 2015
24 September 2015   AIM: RENE
ReNeuron Group plc 
Result of AGM 
Guildford, UK, 24 September 2015: ReNeuron Group plc (the "Company") (AIM: RENE), a leading UK-based stem cell therapy company, announces that all resolutions put to shareholders at today's Annual General Meeting were duly passed.
Enquiries:
ReNeuron
+44 (0)20 3819 8400
Olav Helleb , Chief Executive Officer

Michael Hunt, Chief Financial Officer

Buchanan
+44 (0) 20 7466 5000
Mark Court, Sophie Cowles, Stephanie Watson



Cenkos Securities
+44 (0) 20 7397 8900
Stephen Keys, Dr Christopher Golden (NOMAD and Broker)

Russell Kerr (Sales)

About ReNeuron
ReNeuron is a leading, clinical-stage cell therapy development company. Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need. 
ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments. The Company's therapeutic candidates for stroke disability and critical limb ischaemia are in clinical development and its cell-based treatment for the blindness-causing disease, retinitis pigmentosa, is about to commence clinical development in the US. 
ReNeuron is also advancing a proprietary platform technology to exploit nanoparticles (exosomes) secreted by stem cells as potential new drug candidates targeting a range of cancers.
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.

This information is provided by RNS
The company news service from the London Stock Exchange
  END
RAGUSSURVSAKUAR